Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma

Gene Therapy

Volumn 20, Issue 4, 2013, Pages 386-395

  Schuberth, P C ^a   Jakka, G ^a   Jensen, S M ^b   Wadle, A ^a   Gautschi, F ^a   Haley, D ^b   Haile, S ^c   Mischo, A ^a   Held, G ^d   Thiel, M ^a   Tinguely, M ^a   Bifulco, C B ^b   Fox, B A ^b   Renner, C ^a   Petrausch, U ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

CD8 T cells; chimeric antigen receptor; memory T cells; multiple myeloma; NY ESO 1; re directed T cells

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; NY ESO 1 ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW BIOPSY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL SELECTION; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEMORY T LYMPHOCYTE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GENETIC THERAPY; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CCR7; TRANSDUCTION, GENETIC;

MUS;

EID: 84875928576     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.48     Document Type: Article

References (46)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
2. Gay F, Palumbo A. Management of older patients with multiple myeloma. Blood Rev 2011; 25: 65-73.
3. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
4. Szmania S, Tricot G, van Rhee F. NY-ESO-1 immunotherapy for multiple myeloma. Leuk Lymphoma 2006; 47: 2037-2048.
5. Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B et al. Long-term follow up of a comparison of non-myeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011; 117: 6721-6727.
6. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
7. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004; 4: 371-380.
8. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 2005; 17: 202-210.
9. Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30.
10. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-bind-ing peptide epitopes. J Exp Med 1998; 187: 265-270.
11. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 + cancers. Proc Natl Acad Sci USA 2000; 97: 12198-12203.
12. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005; 105: 3939-3944.
13. Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY et al. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur J Immunol 2004; 34: 2919-2929.
14. Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci USA 2009; 106: 5784-5788.
15. Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005; 5: 928-940.
16. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
17. Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C et al. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res 2001; 61: 1976-1982.
18. Petrausch U, Haley D, Miller W, Floyd K, Urba WJ, Walker E. Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data. Cytometry A 2006; 69: 1162-1173.
19. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117: 1466-1476.
20. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21: 233-240.
21. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL. T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005; 174: 7853-7858.
22. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001; 167: 6123-6131.
23. Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 2003; 63: 2470-2476.
24. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745-763.
25. van Baarle D, Kostense S, van Oers MH, Hamann D, Miedema F. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol 2002; 23: 586-591.
26. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4: 225-234.
27. Ahmed R, Bevan MJ, Reiner SL, Fearon DT. The precursors of memory: models and controversies. Nat Rev Immunol 2009; 9: 662-668.
28. Klebanoff CA, Gattinoni L, Restifo NP. CD8 + T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211: 214-224.
29. Kern F, Khatamzas E, Surel I, Frommel C, Reinke P, Waldrop SL et al. Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur J Immunol 1999; 29: 2908-2915.
30. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8 + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003; 101: 4260-4266.
31. Walker EB, Haley D, Petrausch U, Floyd K, Miller W, Sanjuan N et al. Phenotype and functional characterization of long-term gp100-specific memory CD8 + T cells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res 2008; 14: 5270-5283.
32. Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol 2008; 36: 1318-1328.
33. Neeson P, Shin A, Tainton KM, Guru P, Prince HM, Harrison SJ et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8 + T cells with effector and central memory-like phenotype. Gene Therapy 2010; 17: 1105-1116.
34. Cui W, Kaech SM. Generation of effector CD8 + T cells and their conversion to memory T cells. Immunol Rev 2010; 236: 151-166.
35. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
36. Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 2012; 119: 72-82.
37. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007; 109: 1103-1112.
38. de Carvalho F, Vettore AL, Inaoka RJ, Karia B, Andrade VC, Gnjatic S et al. Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. Cancer Immun 2011; 11: 1.
39. Miyakawa Y, Ohnishi Y, Tomisawa M, Monnai M, Kohmura K, Ueyama Y et al. Establishment of a new model of human multiple myeloma using NOD/SCID/gamma(null)(c) (NOG) mice. Biochem Biophys Res Commun 2004; 313: 258-262.
40. Kirchgessner CU, Patil CK, Evans JW, Cuomo CA, Fried LM, Carter T et al. DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science 1995; 267: 1178-1183.
41. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183: 5563-5574.
42. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
43. Weijtens ME, Willemsen RA, van Krimpen BA, Bolhuis RL. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int J Cancer 1998; 77: 181-187.
44. Hombach A, Schneider C, Sent D, Koch D, Willemsen RA, Diehl V et al. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int J Cancer 2000; 88: 115-120.
45. Hombach A, Koch D, Sircar R, Heuser C, Diehl V, Kruis W et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Therapy 1999; 6: 300-304.
46. Tinguely M, Jenni B, Reineke T, Korol D, Kofler A, Rousson V et al. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays. Am J Surg Pathol 2007; 31: 690-696.